| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000024530 |
| Receipt No. | R000028235 |
| Scientific Title | Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study |
| Date of disclosure of the study information | 2017/04/01 |
| Last modified on | 2019/05/08 (Ver. 14) |
| Basic information | ||
| Public title | Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study | |
| Acronym | NExT-DN | |
| Scientific Title | Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study | |
| Scientific Title:Acronym | NExT-DN | |
| Region |
|
|
| Condition | |||
| Condition | Diabetes
Diabetic nephropathy |
||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate new prognostic and diagnostic indicators of diabetic nephropathy |
| Basic objectives2 | Others |
| Basic objectives -Others | To explore the new therapeutic target of diabetic nephropathy |
| Trial characteristics_1 | |
| Trial characteristics_2 | Others |
| Developmental phase | |
| Assessment | |
| Primary outcomes | eGFR 30-40% decline from baseline
|
| Key secondary outcomes | 1. Investigation of clinicopathologic indocators of renal progression in diabetic nephropathy
I. eGFR decline > 3-5 ml/min/1.73m2/year II. Commencement of dialysis or renal transplantation because of end stage renal disease III. Development of albuminuric stage 2. Investigation of other major complications of diabetes I.Development of diabetic retinopathy II.CVD event III.Death 3. Exploration of new biomarkers to predict diabetic nephropathy in patients with diabetes. I. Diabetic nephrpathy vs no renal disease II. Diabetic nephropathy vs other renal diseases * Investigation of biomarmers to differenciate I and II |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | To evaluate renal disease in patients with diabetes by renal biopsy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients who go to our department from the time after approval of this study by the ethics committee of our hospital to March 31th, 2024.
2. Patients who agreee IC 3. Patients whose age is no less than 20 and no more than 80 at the time of IC. |
|||
| Key exclusion criteria | 1. Patients with diabetes due to other reasons except for type 1 and 2 diabetes, such as steroid-induced diabetes, Cushing syndrome, and genetic diabetes
2. Female in pregnancy or with possibility of pregnancy 3. Patients with high risk of renal biopsy High risk is defined as any one of the following 6 criteria. i. Platelet count < 100,000 (/ul) or definite disordered coagulation ii. Usage of antiplatelet drug and anticoagulated drug which can not be stopped temporarily. iii. Progressive anemia except for renal anemia iv. Patients who can not keep a position in bed during renal biopsy. v. Morphologic problems revealed by image information Specifically, multiple cysts on the puncture line, renal cortex thickness < 10mm, and so on. vi. Patients whom primary physician clinically defined as patients at high risk because of other reasons. 4. Patients under the emergency situations, such as life-threatening and infectious situation. 5. Baseline eGFR < 15ml/min/1.73m2 |
|||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | ||||||
| Division name | Department of Nephrology, Rheumatology, Endocrinology and Metabolism | ||||||
| Zip code | 700-8558 | ||||||
| Address | 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan | ||||||
| TEL | 81-86-235-7235 | ||||||
| junwada@okayama-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | ||||||
| Division name | Department of Nephrology, Rheumatology, Endocrinology and Metabolism | ||||||
| Zip code | 700-8558 | ||||||
| Address | 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan | ||||||
| TEL | 81-86-235-7235 | ||||||
| Homepage URL | |||||||
| kokims-frz@okayama-u.ac.jp | |||||||
| Sponsor | |
| Institute | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Department of Nephrology, Rheumatology, Endocrinology and Metabolism |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nothing |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Center for Innovative Clinical Medicine, Ethics Committee |
| Address | 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan |
| Tel | 086-235-6503 |
| mae6605@adm.okayama-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | Okayama university hospital |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028235 |